CARFILZOMIB

N/A

Manufactured by Onyx Pharmaceuticals, Inc.

45,655 FDA adverse event reports analyzed

Last updated: 2026-04-14

About CARFILZOMIB

CARFILZOMIB is a medication tracked in the FDA Adverse Event Reporting System (FAERS), manufactured by Onyx Pharmaceuticals, Inc.. The most commonly reported adverse reactions for CARFILZOMIB include PLASMA CELL MYELOMA, OFF LABEL USE, DEATH, FATIGUE, THROMBOCYTOPENIA. This page provides a comprehensive breakdown of reported side effects, safety signals, patient demographics, and AI-powered safety analysis for CARFILZOMIB.

Top Adverse Reactions

PLASMA CELL MYELOMA2,946 reports
OFF LABEL USE2,294 reports
DEATH1,740 reports
FATIGUE1,506 reports
THROMBOCYTOPENIA1,473 reports
PNEUMONIA1,340 reports
PYREXIA1,147 reports
DYSPNOEA1,098 reports
DIARRHOEA1,091 reports
ANAEMIA1,075 reports
NEUTROPENIA1,059 reports
NAUSEA1,037 reports
ACUTE KIDNEY INJURY845 reports
DRUG INEFFECTIVE816 reports
ASTHENIA694 reports
HYPERTENSION683 reports
DISEASE PROGRESSION682 reports
NEUROPATHY PERIPHERAL668 reports
INFECTION635 reports
PLATELET COUNT DECREASED591 reports
SEPSIS578 reports
CARDIAC FAILURE539 reports
THERAPY PARTIAL RESPONDER522 reports
VOMITING512 reports
COVID 19476 reports
RENAL FAILURE450 reports
PANCYTOPENIA437 reports
MALAISE431 reports
RASH425 reports
PLASMA CELL MYELOMA REFRACTORY416 reports
FEBRILE NEUTROPENIA390 reports
PRODUCT STORAGE ERROR383 reports
THROMBOTIC MICROANGIOPATHY379 reports
WHITE BLOOD CELL COUNT DECREASED379 reports
PAIN368 reports
INTERCEPTED PRODUCT PREPARATION ERROR367 reports
COUGH355 reports
ATRIAL FIBRILLATION352 reports
DECREASED APPETITE350 reports
PULMONARY EMBOLISM350 reports
HEADACHE348 reports
CONSTIPATION344 reports
BACK PAIN339 reports
UNEVALUABLE EVENT338 reports
LEUKOPENIA324 reports
DEEP VEIN THROMBOSIS311 reports
PLASMA CELL MYELOMA RECURRENT308 reports
INSOMNIA304 reports
CYTOPENIA295 reports
INFLUENZA291 reports
CIRCUMSTANCE OR INFORMATION CAPABLE OF LEADING TO MEDICATION ERROR284 reports
URINARY TRACT INFECTION284 reports
CARDIAC FAILURE CONGESTIVE278 reports
THERAPY NON RESPONDER276 reports
DIZZINESS267 reports
RESPIRATORY FAILURE264 reports
INFUSION RELATED REACTION258 reports
HAEMOGLOBIN DECREASED252 reports
CARDIAC DISORDER251 reports
TOXICITY TO VARIOUS AGENTS247 reports
MYELOSUPPRESSION246 reports
WEIGHT DECREASED242 reports
MUSCLE SPASMS241 reports
TUMOUR LYSIS SYNDROME239 reports
CONFUSIONAL STATE232 reports
DEHYDRATION232 reports
FALL232 reports
CHEST PAIN230 reports
ADVERSE EVENT229 reports
HYPOTENSION223 reports
UPPER RESPIRATORY TRACT INFECTION219 reports
NEUTROPHIL COUNT DECREASED216 reports
RENAL IMPAIRMENT212 reports
OEDEMA PERIPHERAL209 reports
SEPTIC SHOCK209 reports
GENERAL PHYSICAL HEALTH DETERIORATION204 reports
SYNCOPE203 reports
CYTOKINE RELEASE SYNDROME200 reports
FEELING ABNORMAL198 reports
PAIN IN EXTREMITY197 reports
NASOPHARYNGITIS193 reports
CHILLS191 reports
LYMPHOPENIA189 reports
HOSPITALISATION187 reports
PULMONARY OEDEMA187 reports
PLASMACYTOMA186 reports
INTENTIONAL PRODUCT USE ISSUE185 reports
RESPIRATORY TRACT INFECTION185 reports
MYOCARDIAL INFARCTION180 reports
BLOOD PRESSURE INCREASED178 reports
THROMBOSIS175 reports
DRUG INTOLERANCE172 reports
PULMONARY HYPERTENSION170 reports
BONE PAIN167 reports
ARTHRALGIA165 reports
PERIPHERAL SWELLING160 reports
LABORATORY TEST ABNORMAL159 reports
BRONCHITIS158 reports
PLEURAL EFFUSION158 reports
BLOOD CREATININE INCREASED155 reports

Report Outcomes

Out of 27,411 classified reports for CARFILZOMIB:

Serious 76.7%Non-Serious 23.3%

The FDA classifies an adverse event as “serious” if it results in death, hospitalization, disability, congenital anomaly, or requires intervention to prevent permanent damage.

Demographics Breakdown

Reports by Sex

Male12,192 (55.0%)
Female9,920 (44.8%)
Unknown38 (0.2%)

Reports by Age

Age 70754 reports
Age 69750 reports
Age 62708 reports
Age 65705 reports
Age 67698 reports
Age 68693 reports
Age 63675 reports
Age 64661 reports
Age 66657 reports
Age 72637 reports
Age 61622 reports
Age 60620 reports
Age 71619 reports
Age 59557 reports
Age 73525 reports
Age 58522 reports
Age 74501 reports
Age 57494 reports
Age 56478 reports
Age 75467 reports

Demographics reflect voluntary FDA adverse event reporting patterns and may not represent the full patient population.

Frequently Asked Questions

How many FDA adverse event reports are associated with CARFILZOMIB?

This profile reflects 45,655 FDA FAERS reports that mention CARFILZOMIB. Reporting is voluntary and does not prove that the drug caused any listed event.

Which adverse reactions are most often listed for CARFILZOMIB?

Frequently reported terms in FAERS include PLASMA CELL MYELOMA, OFF LABEL USE, DEATH, FATIGUE, THROMBOCYTOPENIA, PNEUMONIA. Rankings reflect reporting volume in this dataset, not confirmed side effect rates in the general population.

Who manufactures CARFILZOMIB?

Labeling and FAERS entries often list Onyx Pharmaceuticals, Inc. in connection with CARFILZOMIB. Always verify the specific product and NDC with your pharmacist.

Important Disclaimer: This content is generated by AI analysis of FDA adverse event reports and is provided for informational purposes only. It is not medical advice. Adverse event reports submitted to the FDA do not prove that a medication caused the reported side effect. Always consult your healthcare provider before starting, stopping, or changing any medication. If you experience a serious side effect, contact your doctor or call 911 immediately.